Lilac Solutions vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 27)

Lilac Solutions

EmergingClimate & Energy

General

Oakland DLE lithium extraction technology ($318M total, $145M T. Rowe Price Series C); 5th gen 20x production rates with 1-acre = 10,000-acre evaporation pond efficiency and Great Salt Lake/Argentina deployments competing with SLB for lithium supply.

AI VisibilityBeta
Overall Score
D27
Category Rank
#728 of 1167
AI Consensus
46%
Trend
stable
Per Platform
ChatGPT
22
Perplexity
36
Gemini
18

About

Lilac Solutions is an Oakland, California-based direct lithium extraction (DLE) technology company — backed with over $318 million in total funding including a $145 million Series C led by T. Rowe Price and Presidio Ventures — commercializing a proprietary ion exchange process that extracts lithium from brine resources with 70-98% efficiency using ceramic beads coated with nano-materials, achieving the same lithium output from a 1-acre system that conventional evaporation pond methods require 10,000 acres to produce. Founded in 2016 from CEO Dave Snydacker's PhD research at Northwestern University, Lilac was acquired new CEO Raef Sully (former CEO of Nutrien's $10 billion business unit) in 2024 to lead commercial scaling. In 2025, Lilac unveiled its fifth-generation DLE technology achieving 20x higher lithium production rates and 10,000 operational cycles before replacement — orders of magnitude better than competing technologies. Active projects include the Kachi project in Argentina (with Lake Resources), the Great Salt Lake project in Utah (targeting 3,000 tonnes per year by 2026), and the Neptune project in Germany. Lilac's manufacturing facility in Fernley, Nevada produces the ion exchange beads for commercial deployment. Investors include Breakthrough Energy Ventures.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

27
Overall Score
90
#728
Category Rank
#9
46
AI Consensus
60
stable
Trend
stable
22
ChatGPT
99
36
Perplexity
99
18
Gemini
83
21
Claude
96
37
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.